COSCIENS Biopharma Inc.
Close on Oct 19, 2026
- Market cap
- $24.10M
- P/E (TTM)
- –
- Dividend yield
- –
About COSCIENS Biopharma
Perfumes, Cosmetics & Other Toilet Preparations, SIC 2844
COSCIENS Biopharma Inc. is a biopharmaceutical enterprise focused on the extraction, production, and commercialization of active ingredients from natural sources. Its operations encompass biopharmaceutical development as well as active ingredients for the nutraceuticals market, notably oat-based pipeline products such as oat-beta glucan and avenanthramides, along with yeast-derived beta glucan. The organization also advances and scales proprietary Pressurized Gas eXpanded technology. Its customer base includes commercial distributors, healthcare partners, and biopharmaceutical clients across global regions.
The company engages in business across international territories, recording commercial and partner activities in countries such as the United States, Germany, the United Kingdom, and Colombia. Executive offices and corporate headquarters are located in Toronto, Ontario, Canada.
Summary of the business section of COSCIENS Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- COSCIENS Biopharma Inc.
- Headquarters
- Toronto, A6
- Address
- C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53 M5K 1E7
- Phone
- (843) 900-3201
- Website
- sedarplus.ca
- Employees
- 28, Dec 31, 2025
- Industry
- Perfumes, Cosmetics & Other Toilet Preparations
- Incorporated in
- A6
- Fiscal year ends
- December 31
- Auditor
- Deloitte LLP, Montreal, Canada
Stock & identifiers
- Ticker
- CSCIF
- Exchange
- OTC
- IPO date
- May 10, 2000
- Shares outstanding
- 3M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-4 reverse, May 3, 2024; 1-for-25 reverse, Nov 3, 2022; 1-for-25 reverse, Jul 21, 2022; 1-for-100 reverse, Nov 20, 2015; 1-for-6 reverse, Oct 5, 2012
- SEC CIK
- 1113423
- CUSIP
- 22112H101
- ISIN
- US22112H1014
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
COSCIENS Biopharma's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“at December 31, 2025, we had a total of 28 active employees, of which 23 were based in Canada, 4 were based in Frankfurt, Germany and”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 6, 2026 | Deregistration | Termination of SEC registration (Form 15) |
| Aug 26, 2025 | Delisting | Notice of delisting from exchange (Form 25) |
| Aug 7, 2024 | Name change | Name changed from Aeterna Zentaris Inc. to COSCIENS Biopharma Inc. |
| Apr 14, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 25, 2004 | Name change | Name changed from AETERNA LABORATORIES INC to Aeterna Zentaris Inc. |